{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:17:36Z","timestamp":1786997856842,"version":"build-2736575974"},"reference-count":147,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ucl.2025.09.006","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:36:22Z","timestamp":1761827782000},"page":"15-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Molecular Biomarkers for Localized Prostate Cancer"],"prefix":"10.1016","volume":"53","author":[{"given":"Kevin","family":"Shee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Cooperberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ucl.2025.09.006_bib1","doi-asserted-by":"crossref","first-page":"9067","DOI":"10.1200\/JCO.2004.01.0454","article-title":"Reporting recommendations for tumor marker prognostic studies","volume":"23","author":"McShane","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ucl.2025.09.006_bib2","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/jnci\/djn326","article-title":"Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design","volume":"100","author":"Pepe","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ucl.2025.09.006_bib3","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/jnci\/djp335","article-title":"Use of archived specimens in evaluation of prognostic and predictive biomarkers","volume":"101","author":"Simon","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ucl.2025.09.006_bib4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.eururo.2019.05.013","article-title":"The state of the science on prostate cancer biomarkers: the San Francisco consensus statement","volume":"76","author":"Cooperberg","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib5","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jama.294.1.66","article-title":"Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng\/ml or lower","volume":"294","author":"Thompson","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ucl.2025.09.006_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b3537","article-title":"Prostate specific antigen for early detection of prostate cancer: longitudinal study","volume":"339","author":"Holmstrom","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.ucl.2025.09.006_bib7","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1001\/jamainternmed.2019.0280","article-title":"Association of treatment with 5alpha-reductase inhibitors with time to diagnosis and mortality in prostate cancer","volume":"179","author":"Sarkar","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ucl.2025.09.006_bib8","doi-asserted-by":"crossref","DOI":"10.1007\/s11606-025-09737-7","article-title":"Smarter screening and treatment (S3T): mitigating harm via age- & prostate specific antigen-stratified screening","author":"Nie","year":"2025","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.ucl.2025.09.006_bib9","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.eururo.2018.08.032","article-title":"Baseline prostate-specific antigen level in midlife and aggressive prostate cancer in black men","volume":"75","author":"Preston","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f2023","article-title":"Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study","volume":"346","author":"Vickers","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.ucl.2025.09.006_bib11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.eururo.2013.08.005","article-title":"Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European randomized study of screening for prostate cancer","volume":"65","author":"Bokhorst","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib12","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.eururo.2023.03.016","article-title":"A detailed evaluation of the effect of prostate-specific antigen-based screening on morbidity and mortality of prostate cancer: 21-year follow-up results of the rotterdam section of the European randomised study of screening for prostate cancer","volume":"84","author":"de","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib13","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1470-2045(10)70146-7","article-title":"Mortality results from the Goteborg randomised population-based prostate-cancer screening trial","volume":"11","author":"Hugosson","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ucl.2025.09.006_bib14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.7326\/M16-2586","article-title":"Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials","volume":"167","author":"Tsodikov","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ucl.2025.09.006_bib15","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1001\/jamaoncol.2022.4319","article-title":"Association of prostate-specific antigen screening rates with subsequent metastatic prostate cancer incidence at US veterans health administration facilities","volume":"8","author":"Bryant","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ucl.2025.09.006_bib16","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1056\/NEJMcp2209151","article-title":"Screening for prostate cancer","volume":"388","author":"Pinsky","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ucl.2025.09.006_bib17","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1001\/jama.279.19.1542","article-title":"Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial","volume":"279","author":"Catalona","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.ucl.2025.09.006_bib18","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/JU.0000000000003603","article-title":"Free PSA and clinically significant and fatal prostate cancer in the PLCO screening trial","volume":"210","author":"Yim","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib19","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.juro.2006.09.039","article-title":"Prostate specific antigen density correlates with features of prostate cancer aggressiveness","volume":"177","author":"Kundu","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib20","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.juro.2017.03.130","article-title":"The value of PSA density in combination with PI-RADS for the accuracy of prostate cancer prediction","volume":"198","author":"Distler","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.urology.2017.04.015","article-title":"Re-examining prostate-specific antigen (PSA) density: defining the optimal PSA range and patients for using PSA density to predict prostate cancer using extended template biopsy","volume":"105","author":"Jue","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2025.09.006_bib22","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/cncr.21267","article-title":"The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng\/mL","volume":"104","author":"Stephan","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ucl.2025.09.006_bib23","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.juro.2018.05.016","article-title":"Prostate specific antigen density as a predictor of clinically significant prostate cancer when the prostate specific antigen is in the diagnostic gray zone: defining the optimum cutoff point stratified by race and body mass index","volume":"200","author":"Aminsharifi","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib24","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1373\/clinchem.2012.195784","article-title":"Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer","volume":"59","author":"Stephan","year":"2013","journal-title":"Clin Chem"},{"key":"10.1016\/j.ucl.2025.09.006_bib25","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.juro.2014.10.121","article-title":"The prostate health index selectively identifies clinically significant prostate cancer","volume":"193","author":"Loeb","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib26","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1515\/cclm-2022-0354","article-title":"Prostate health index (PHI) as a reliable biomarker for prostate cancer: a systematic review and meta-analysis","volume":"60","author":"Agnello","year":"2022","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.ucl.2025.09.006_bib27","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2014.10.021","article-title":"A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer","volume":"68","author":"Parekh","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib28","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.eururo.2024.04.037","article-title":"Performance of 4Kscore as a reflex test to prostate-specific antigen in the GOTEBORG-2 prostate cancer screening trial","volume":"86","author":"Josefsson","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.eururo.2014.08.010","article-title":"Comparison between the four-kallikrein panel and prostate health index for predicting prostate cancer","volume":"68","author":"Nordstrom","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib30","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.eururo.2017.03.025","volume":"72","author":"Klein","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib31","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/JU.0000000000000185","article-title":"Clinical validation of IsoPSA, a single parameter, structure based assay for improved detection of high grade prostate cancer","volume":"201","author":"Stovsky","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2022.06.002","article-title":"Clinical validation of IsoPSA, a single parameter, structure-focused assay for improved detection of prostate cancer: a prospective, multicenter study","volume":"40","author":"Klein","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ucl.2025.09.006_bib33","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.urology.2023.03.014","article-title":"Using IsoPSA with prostate imaging reporting and data system score may help refine biopsy decision making in patients with elevated PSA","volume":"176","author":"Benidir","year":"2023","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2025.09.006_bib34","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa2407934","article-title":"Assessment of a polygenic risk score in screening for prostate cancer","volume":"392","author":"McHugh","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ucl.2025.09.006_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2022.09.006","article-title":"How well do polygenic risk scores identify men at high risk for prostate cancer? systematic review and meta-analysis","volume":"21","author":"Siltari","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ucl.2025.09.006_bib36","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/S1470-2045(15)00361-7","article-title":"Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study","volume":"16","author":"Gronberg","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ucl.2025.09.006_bib37","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/JU.0000000000004437","article-title":"A comparison of stockholm3, serum biomarkers, and risk calculators to predict prostate cancer in a racially and ethnically diverse cohort: evaluation of the stockholm3 multiethnic SEPTA trial","volume":"213","author":"Lazarovich","year":"2025","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib38","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa2100852","article-title":"MRI-targeted or standard biopsy in prostate cancer screening","volume":"385","author":"Eklund","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ucl.2025.09.006_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2020.03.010","article-title":"Development and evaluation of the MiCheck test for aggressive prostate cancer","volume":"38","author":"Shore","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ucl.2025.09.006_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2023.08.005","article-title":"Development and evaluation of the MiCheck(R) Prostate test for clinically significant prostate cancer","volume":"41","author":"Shore","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ucl.2025.09.006_bib41","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1200\/JCO.2013.52.8505","article-title":"Can urinary PCA3 supplement PSA in the early detection of prostate cancer?","volume":"32","author":"Wei","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ucl.2025.09.006_bib42","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.eururo.2014.08.011","article-title":"The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men","volume":"66","author":"Vedder","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib43","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.juro.2013.02.3184","article-title":"Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy","volume":"190","author":"Scattoni","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib44","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1001\/jamaoncol.2024.0455","article-title":"Development and validation of an 18-gene urine test for high-grade prostate cancer","volume":"10","author":"Tosoian","year":"2024","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.006_bib45","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/JU.0000000000004421","article-title":"Clinical validation of MyProstateScore 2.0 testing using first-catch, non-digital rectal examination urine","volume":"213","author":"Tosoian","year":"2025","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib46","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-14-3334","article-title":"Identification of a candidate gene panel for the early diagnosis of prostate cancer","volume":"21","author":"Leyten","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2025.09.006_bib47","article-title":"A meta-analysis for the diagnostic accuracy of SelectMDx in prostate cancer","volume":"19","author":"Wu","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.ucl.2025.09.006_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0271981","article-title":"Combination of PI-RADS score and mRNA urine test-A novel scoring system for improved detection of prostate cancer","volume":"17","author":"Katzendorn","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.ucl.2025.09.006_bib49","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1001\/jamaoncol.2016.0097","article-title":"A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy","volume":"2","author":"McKiernan","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ucl.2025.09.006_bib50","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41391-021-00456-8","article-title":"Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies","volume":"25","author":"Margolis","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ucl.2025.09.006_bib51","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-2490-12-16","article-title":"A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection","volume":"12","author":"Van Neste","year":"2012","journal-title":"BMC Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib52","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.juro.2012.08.219","article-title":"Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study","volume":"189","author":"Stewart","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib53","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.juro.2014.04.013","article-title":"Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies","volume":"192","author":"Partin","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib54","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/pros.23191","article-title":"Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies","volume":"76","author":"Van Neste","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.ucl.2025.09.006_bib55","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.juro.2017.08.107","article-title":"Does early prostate specific antigen doubling time after radical prostatectomy, calculated prior to prostate specific antigen recurrence, correlate with prostate cancer outcomes? A Report from the SEARCH database Group","volume":"199","author":"Teeter","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib56","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ijrobp.2005.03.008","article-title":"Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy","volume":"63","author":"Lee","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ucl.2025.09.006_bib57","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1470-2045(10)70295-3","article-title":"Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study","volume":"12","author":"Cuzick","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ucl.2025.09.006_bib58","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/bjc.2012.39","article-title":"Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort","volume":"106","author":"Cuzick","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ucl.2025.09.006_bib59","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.juro.2014.02.003","article-title":"Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy","volume":"192","author":"Bishoff","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib60","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2012.46.4396","article-title":"Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort","volume":"31","author":"Cooperberg","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ucl.2025.09.006_bib61","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.ijrobp.2013.04.043","article-title":"Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy","volume":"86","author":"Freedland","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ucl.2025.09.006_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2018.03.011","article-title":"Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance","volume":"36","author":"Lin","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ucl.2025.09.006_bib63","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.eururo.2014.05.004","article-title":"A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling","volume":"66","author":"Klein","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib64","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.euf.2021.03.015","article-title":"Association between oncotype DX genomic prostate score and adverse tumor pathology after radical prostatectomy","volume":"8","author":"Covas Moschovas","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.ucl.2025.09.006_bib65","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.urology.2017.02.052","article-title":"Use of a 17-gene prognostic assay in contemporary urologic practice: results of an interim analysis in an observational cohort","volume":"107","author":"Eure","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2025.09.006_bib66","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.urpr.2015.02.007","article-title":"Utility of the oncotype DX((R)) prostate cancer assay in clinical practice for treatment selection in men newly diagnosed with prostate cancer: a retrospective chart review analysis","volume":"2","author":"Dall'Era","year":"2015","journal-title":"Urol Pract"},{"key":"10.1016\/j.ucl.2025.09.006_bib67","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1200\/JCO.19.02267","article-title":"17-gene genomic prostate score test results in the canary prostate active surveillance study (PASS) cohort","volume":"38","author":"Lin","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ucl.2025.09.006_bib68","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.eururo.2014.11.030","article-title":"A Biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer","volume":"68","author":"Cullen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib69","article-title":"The 17-gene genomic prostate score assay is prognostic for biochemical failure in men with localized prostate cancer after radiation therapy at a community cancer center","volume":"8","author":"Canter","year":"2023","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ucl.2025.09.006_bib70","article-title":"GPS assay association with long-term cancer outcomes: twenty-year risk of distant metastasis and prostate cancer-specific mortality","volume":"5","author":"Brooks","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ucl.2025.09.006_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066855","article-title":"Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy","volume":"8","author":"Erho","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ucl.2025.09.006_bib72","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1200\/JCO.2016.70.2811","article-title":"Individual patient-level meta-analysis of the performance of the decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease","volume":"35","author":"Spratt","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ucl.2025.09.006_bib73","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2020.11.021","article-title":"A systematic review of the evidence for the decipher genomic classifier in prostate cancer","volume":"79","author":"Jairath","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib74","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1001\/jamaoncol.2020.7671","article-title":"Validation of a 22-gene genomic classifier in patients with recurrent prostate cancer: an ancillary study of the NRG\/RTOG 9601 randomized clinical trial","volume":"7","author":"Feng","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ucl.2025.09.006_bib75","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.urology.2016.01.012","article-title":"Decipher genomic classifier measured on prostate biopsy predicts metastasis risk","volume":"90","author":"Klein","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2025.09.006_bib76","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.eururo.2017.05.009","article-title":"Ability of a genomic classifier to predict metastasis and prostate cancer-specific mortality after radiation or surgery based on needle biopsy specimens","volume":"72","author":"Nguyen","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib77","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ijrobp.2023.04.010","article-title":"Genomic classifier performance in intermediate-risk prostate cancer: results from NRG oncology\/RTOG 0126 randomized phase 3 trial","volume":"117","author":"Spratt","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ucl.2025.09.006_bib78","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ijrobp.2022.12.035","article-title":"Analysis of a biopsy-based genomic classifier in high-risk prostate cancer: meta-analysis of the nrg oncology\/radiation therapy oncology group 9202, 9413, and 9902 phase 3 randomized trials","volume":"116","author":"Nguyen","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ucl.2025.09.006_bib79","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41746-022-00613-w","article-title":"Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials","volume":"5","author":"Esteva","year":"2022","journal-title":"npj Digit Med"},{"key":"10.1016\/j.ucl.2025.09.006_bib80","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.eururo.2024.06.019","article-title":"Meta-analysis of individual patient-level data for a multimodal artificial intelligence biomarker in high-risk prostate cancer: results from six NRG\/RTOG phase 3 randomized trials","volume":"86","author":"Spratt","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib81","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300023","article-title":"Artificial intelligence predictive model for hormone therapy use in prostate cancer","volume":"2","author":"Spratt","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.ucl.2025.09.006_bib82","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1158\/1078-0432.CCR-08-2927","article-title":"Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States","volume":"15","author":"Mosquera","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2025.09.006_bib83","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.clgc.2015.12.001","article-title":"Urine TMPRSS2: ERG fusion transcript as a biomarker for prostate cancer: literature review","volume":"14","author":"Sanguedolce","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ucl.2025.09.006_bib84","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001970","article-title":"Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA","volume":"3","author":"Tomlins","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ucl.2025.09.006_bib85","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.urology.2021.11.033","article-title":"Urinary MyProstateScore (MPS) to rule out clinically-significant cancer in men with equivocal (PI-RADS 3) multiparametric MRI: addressing an unmet clinical need","volume":"164","author":"Tosoian","year":"2022","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2025.09.006_bib86","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1097\/01.ju.0000173907.84852.ec","article-title":"The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy","volume":"174","author":"Freedland","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib87","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.eururo.2007.08.047","article-title":"PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database","volume":"53","author":"Freedland","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib88","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eururo.2024.04.034","article-title":"Risk stratification of patients with recurrence after primary treatment for prostate cancer: a systematic review","volume":"86","author":"Weiner","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib89","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.eururo.2005.10.027","article-title":"Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng\/ml","volume":"49","author":"Shariat","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib90","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/JU.0000000000000808","article-title":"A high percent free prostate specific antigen in the setting of biochemical recurrence after radical prostatectomy is associated with poorer outcomes: a validation study using prospectively collected biobank specimens","volume":"204","author":"Woon","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib91","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.euo.2023.11.011","article-title":"The impact of delayed radical prostatectomy on recurrence outcomes after initial active surveillance: results from a large institutional cohort","volume":"7","author":"Shee","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ucl.2025.09.006_bib92","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.euo.2024.09.008","article-title":"Determining long-term prostate cancer outcomes for active surveillance patients without early disease progression: implications for slowing or stopping surveillance","volume":"8","author":"Shee","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ucl.2025.09.006_bib93","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.urology.2007.01.087","article-title":"Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure","volume":"69","author":"Radwan","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2025.09.006_bib94","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.juro.2012.07.106","article-title":"Value of prostate specific antigen density and percent free prostate specific antigen for prostate cancer prognosis","volume":"188","author":"Busch","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib95","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.juro.2008.01.032","article-title":"Prostate specific antigen versus prostate specific antigen density as a prognosticator of pathological characteristics and biochemical recurrence following radical prostatectomy","volume":"179","author":"Magheli","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib96","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0022-5347(05)64841-0","article-title":"Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score","volume":"168","author":"Freedland","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib97","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12885-024-12029-8","article-title":"Pretreatment prostate-specific antigen density as a predictor of biochemical recurrence in patients with prostate cancer: a meta-analysis","volume":"24","author":"Cui","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ucl.2025.09.006_bib98","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1097\/JU.0000000000002852","article-title":"Impact of prostate health index results for prediction of biopsy grade reclassification during active surveillance","volume":"208","author":"Filson","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2023.08.011","article-title":"Baseline prostate health index risk category and risk category changes during active surveillance predict grade reclassification","volume":"41","author":"de la Calle","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ucl.2025.09.006_bib100","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/bju.15101","article-title":"Prostate Health Index and multiparametric magnetic resonance imaging to predict prostate cancer grade reclassification in active surveillance","volume":"126","author":"Schwen","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2025.09.006_bib101","article-title":"Role of prostate health index to predict Gleason score upgrading and high-risk prostate cancer in radical prostatectomy specimens","volume":"11","author":"Kim","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ucl.2025.09.006_bib102","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.eururo.2014.07.034","article-title":"Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer: results from a multicentric european prospective study","volume":"68","author":"Fossati","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib103","doi-asserted-by":"crossref","first-page":"79279","DOI":"10.18632\/oncotarget.17476","article-title":"The prostate health index PHI predicts oncological outcome and biochemical recurrence after radical prostatectomy - analysis in 437 patients","volume":"8","author":"Maxeiner","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ucl.2025.09.006_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2015.05.007","article-title":"Preoperative prostate health index is an independent predictor of early biochemical recurrence after radical prostatectomy: results from a prospective single-center study","volume":"33","author":"Lughezzani","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ucl.2025.09.006_bib105","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/bju.14041","article-title":"Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5alpha-reductase inhibitors","volume":"121","author":"Fradet","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2025.09.006_bib106","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/pcan.2017.16","article-title":"Longitudinal assessment of urinary PCA3 for predicting prostate cancer grade reclassification in favorable-risk men during active surveillance","volume":"20","author":"Tosoian","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ucl.2025.09.006_bib107","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.urology.2017.05.028","article-title":"Prostate cancer antigen 3 score does not predict for adverse pathologic features at radical prostatectomy or for progression-free survival in clinically localized, intermediate- and high-risk prostate cancer","volume":"107","author":"Hegde","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2025.09.006_bib108","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1464-410X.2011.10682.x","article-title":"The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy","volume":"110","author":"Durand","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2025.09.006_bib109","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2010.10.024","article-title":"Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging","volume":"59","author":"Auprich","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib110","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41391-024-00898-w","article-title":"Evaluating 4Kscore's role in predicting progression on active surveillance for prostate cancer independently of clinical information and PIRADS score","volume":"28","author":"Hougen","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ucl.2025.09.006_bib111","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.eururo.2016.11.017","article-title":"Evaluating the four kallikrein panel of the 4kscore for prediction of high-grade prostate cancer in men in the canary prostate active surveillance study","volume":"72","author":"Lin","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib112","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41416-020-0914-7","article-title":"A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy","volume":"123","author":"Haese","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ucl.2025.09.006_bib113","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/s41416-021-01661-x","article-title":"Independent validation of a pre-specified four-kallikrein marker model for prediction of adverse pathology and biochemical recurrence","volume":"126","author":"Rasmussen","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ucl.2025.09.006_bib114","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/JU.0000000000001007","article-title":"Prespecified 4-Kallikrein marker model at age 50 or 60 for early detection of lethal prostate cancer in a large population based cohort of asymptomatic men followed for 20 years","volume":"204","author":"Vertosick","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib115","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1001\/jamaoncol.2024.5398","article-title":"Polygenic risk score and upgrading in patients with prostate cancer receiving active surveillance","volume":"11","author":"Goss","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ucl.2025.09.006_bib116","doi-asserted-by":"crossref","first-page":"75979","DOI":"10.18632\/oncotarget.18275","article-title":"Genetic risk score to predict biochemical recurrence after radical prostatectomy in prostate cancer: prospective cohort study","volume":"8","author":"Oh","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ucl.2025.09.006_bib117","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00345-022-03937-0","article-title":"Pre-diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post-prostatectomy pathology outcome","volume":"40","author":"Kretschmer","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib118","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.eururo.2018.01.017","article-title":"Refined analysis of prostate-specific antigen kinetics to predict prostate cancer active surveillance outcomes","volume":"74","author":"Cooperberg","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib119","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/ijc.22161","article-title":"PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section","volume":"120","author":"Khatami","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ucl.2025.09.006_bib120","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/cncr.23575","article-title":"Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance","volume":"113","author":"Al Otaibi","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ucl.2025.09.006_bib121","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.juro.2010.12.042","article-title":"The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer","volume":"185","author":"Whitson","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib122","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1200\/JCO.2009.25.7311","article-title":"Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program","volume":"28","author":"Ross","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ucl.2025.09.006_bib123","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1464-410X.2012.11295.x","article-title":"Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients","volume":"111","author":"Iremashvili","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2025.09.006_bib124","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.urology.2010.04.071","article-title":"Does PSADT after radical prostatectomy correlate with overall survival?--a report from the SEARCH database group","volume":"77","author":"Teeter","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2025.09.006_bib125","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part i: introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib126","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.19.02768","article-title":"Molecular biomarkers in localized prostate cancer: ASCO guideline","volume":"38","author":"Eggener","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ucl.2025.09.006_bib127","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/JU.0000000000003491","article-title":"Early detection of prostate cancer: AUA\/SUO guideline part i: prostate cancer screening","volume":"210","author":"Wei","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib128","unstructured":"EAU Guidelines. edn presented at the EAU Annual Congress Madrid 2025. ISBN 978-94-92671-29-5."},{"key":"10.1016\/j.ucl.2025.09.006_bib129","unstructured":"National Comprehensive Cancer Network, Prostate Cancer (Version 1.2025)."},{"key":"10.1016\/j.ucl.2025.09.006_bib130","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/JU.0000000000003492","article-title":"Early detection of prostate cancer: AUA\/SUO guideline part II: considerations for a prostate biopsy","volume":"210","author":"Wei","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib131","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.2018.3712","article-title":"Prostate-Specific antigen-based screening for prostate cancer: evidence report and systematic review for the us preventive services task force","volume":"319","author":"Fenton","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ucl.2025.09.006_bib132","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.urology.2004.10.064","article-title":"Evidence suggesting PSA cutpoint of 2.5 ng\/mL for prompting prostate biopsy: review of 36,316 biopsies","volume":"65","author":"Gilbert","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2025.09.006_bib133","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jama.2024.3841","article-title":"Prostate cancer screening with PSA, kallikrein panel, and MRI: the ProScreen randomized trial","volume":"331","author":"Auvinen","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.ucl.2025.09.006_bib134","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1056\/NEJMoa2209454","article-title":"Prostate cancer screening with PSA and MRI followed by targeted biopsy only","volume":"387","author":"Hugosson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ucl.2025.09.006_bib135","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.euf.2017.11.010","article-title":"Prostate magnetic resonance imaging interpretation varies substantially across radiologists","volume":"5","author":"Sonn","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.ucl.2025.09.006_bib136","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1148\/radiol.2020190646","article-title":"Variability of the positive predictive value of PI-RADS for prostate MRI across 26 centers: experience of the society of abdominal radiology prostate cancer disease-focused panel","volume":"296","author":"Westphalen","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.ucl.2025.09.006_bib137","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jval.2021.02.009","article-title":"Economic evaluation of urine-based or magnetic resonance imaging reflex tests in men with intermediate prostate-specific antigen levels in the United States","volume":"24","author":"Jiao","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.ucl.2025.09.006_bib138","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1002\/cncr.22262","article-title":"Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy","volume":"107","author":"Cooperberg","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ucl.2025.09.006_bib139","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.eururo.2024.07.013","article-title":"A novel artificial intelligence-powered tool for precise risk stratification of prostate cancer progression in patients with clinical intermediate risk","volume":"87","author":"Nair","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib140","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/jnci\/djae139","article-title":"Predicting prostate cancer grade reclassification on active surveillance using a deep learning-based grading algorithm","volume":"116","author":"Ding","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ucl.2025.09.006_bib141","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.20.02997","article-title":"Impact of a genomic test on treatment decision in a predominantly african american population with favorable-risk prostate cancer: a randomized trial","volume":"39","author":"Murphy","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ucl.2025.09.006_bib142","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1200\/JCO.2008.17.3468","article-title":"Lack of comprehension of common prostate cancer terms in an underserved population","volume":"27","author":"Kilbridge","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ucl.2025.09.006_bib143","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamaoncol.2020.6086","article-title":"Regional adoption of commercial gene expression testing for prostate cancer","volume":"7","author":"Leapman","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ucl.2025.09.006_bib144","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/bju.13793","article-title":"Prostate cancer screening practices in a large, integrated health system: 2007-2014","volume":"120","author":"Misra-Hebert","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2025.09.006_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2023.04.020","article-title":"Insurer coverage of prostate cancer biomarkers","volume":"41","author":"Brant","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ucl.2025.09.006_bib146","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.juro.2017.01.058","article-title":"Racial variation in the utility of urinary biomarkers PCA3 and T2ERG in a large multicenter study","volume":"198","author":"O'Malley","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2025.09.006_bib147","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1002\/cncr.35392","article-title":"Out-of-pocket costs for diagnostic testing following abnormal prostate cancer screening among privately insured men","volume":"130","author":"Srivastava","year":"2024","journal-title":"Cancer"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014325000898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014325000898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:05:17Z","timestamp":1765289117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014325000898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":147,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0094014325000898"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2025.09.006","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Biomarkers for Localized Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2025.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}